Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Linvolseltamab (anticuerpo biespecífico anti-BCMA x anti-CD3) más otros tratamientos contra el cáncer para participantes con mieloma múltiple en recaída o refractario (LINKER-MM2)

2 de noviembre de 2026 actualizado por: Regeneron Pharmaceuticals

Estudio de fase 1b de REGN5458 (anticuerpo biespecífico anti-BCMA x anti-CD3) más otros tratamientos contra el cáncer para pacientes con mieloma múltiple en recaída o refractario

This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab has previously been studied as a single agent (without other cancer treatments) in participants with multiple myeloma that returned after prior therapies and needed to be treated again.

In the initial study, some participants treated with linvoseltamab had improvement of their myeloma, including complete responses (no evidence of myeloma in their bodies).

This study is the first time linvoseltamab will be combined with other cancer therapies.

The main goal is to understand if linvoseltamab can be given safely with other cancer treatments, and if so, what dose of linvoseltamab should be used for each combination.

The study is looking at several other research questions, including:

  • How many participants treated with linvoseltamab in combination with each of the other cancer treatments have improvement of their multiple myeloma
  • What side effects may happen from taking linvoseltamab together with another cancer treatment
  • How much study drug is in the blood at different times
  • Whether the body makes antibodies against the study drug(s) (which could make the study drug(s) less effective or could lead to side effects)

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Estimado)

317

Fase

  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

      • Barcelona, España, 08035
        • Reclutamiento
        • Hospital Universitario Vall d'Hebron
      • Barcelona, España, 08036
        • Reclutamiento
        • Hospital Clinic de Barcelona
      • Barcelona, España, 08908
        • Reclutamiento
        • Institut Catala d'Oncologia (ICO) - Hospital Duran i Reynals,
      • Madrid, España, 28050
        • Reclutamiento
        • Hospital Universitario HM Sanchinarro
      • Madrid, España, 28027
        • Reclutamiento
        • Clinica Universidad de Navarra - Madrid
      • Madrid, España, 28006
        • Reclutamiento
        • Universitaru Hospital La Princesa
      • Madrid, España, 28041
        • Reclutamiento
        • University Hospital and Research Institute
      • Madrid, España, 28034
        • Reclutamiento
        • Hospital Universitario Ramon y Cajal - Servicio de Psiquiatria
      • Salamanca, España, 37007
        • Reclutamiento
        • University Hospital of Salamanca
    • A Coruna
      • Santiago de Compostela, A Coruna, España, 15706
        • Reclutamiento
        • Hospital Clinico Universitario de Santiago
    • Barcelona
      • Badalona, Barcelona, España, 08916
        • Reclutamiento
        • Hospital Germans Trias i Pujol
    • Cantabria
      • Santander, Cantabria, España, 39008
        • Reclutamiento
        • Hospital Universitario Marques de Valdecilla
    • Madrid
      • Pozuelo de Alarcón, Madrid, España, 28223
        • Reclutamiento
        • Hospital Universitario Quiron Salud Madrid
    • Navarre
      • Pamplona, Navarre, España, 31008
        • Reclutamiento
        • Clinica Universidad de Navarra
    • California
      • La Jolla, California, Estados Unidos, 92037
        • Reclutamiento
        • Scripps Clinic Torrey Pines
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30004
        • Reclutamiento
        • Winship Cancer Institute of Emory University
    • Indiana
      • Indianapolis, Indiana, Estados Unidos, 46202
        • Reclutamiento
        • Indiana University Health Simon Cancer Center
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02215
        • Reclutamiento
        • Dana Farber/Harvard Cancer Center
    • Michigan
      • Detroit, Michigan, Estados Unidos, 48201
        • Reclutamiento
        • Karmanos Cancer Institute
    • Minnesota
      • Rochester, Minnesota, Estados Unidos, 55905
        • Reclutamiento
        • Mayo Clinic
    • New York
      • New York, New York, Estados Unidos, 10021
        • Reclutamiento
        • Weill Cornell Medicine/New York Presbyterian Hospital
      • New York, New York, Estados Unidos, 10032
        • Reclutamiento
        • New York Presbyterian Hospital Columbia University Medical Center
    • North Carolina
      • Chapel Hill, North Carolina, Estados Unidos, 27599
        • Reclutamiento
        • University of North Carolina at Chapel Hill
      • Winston-Salem, North Carolina, Estados Unidos, 27157
        • Reclutamiento
        • Wake Forest University Health Sciences
    • Ohio
      • Columbus, Ohio, Estados Unidos, 43210
        • Reclutamiento
        • The Ohio State University James Cancer Hospital
    • Texas
      • Dallas, Texas, Estados Unidos, 75390
        • Reclutamiento
        • University of Texas Southwestern
    • Washington
      • Seattle, Washington, Estados Unidos, 98108
        • Reclutamiento
        • VA Puget Sound Health Care System
      • Angers, Francia, 49933
        • Reclutamiento
        • Centre Hospitalier Universitaire Angers
      • Montpellier, Francia, 34295
        • Reclutamiento
        • CHU Montpellier - Departement D'Hematologie
      • Paris, Francia, 75571
        • Reclutamiento
        • Saint Antoine Hospital
      • Villejuif, Francia, 94805
        • Reclutamiento
        • Institut Gustave Roussy
    • New Aquitaine
      • Poitiers, New Aquitaine, Francia, 86021
        • Reclutamiento
        • Centre Hospitalier Universitaire (CHU) de Poitiers
    • Nord
      • Lille, Nord, Francia, 59037
        • Reclutamiento
        • CHU de Lille - Rue Michel Polonovski
    • Pays de la Loire Region
      • Nantes, Pays de la Loire Region, Francia, 44093
        • Reclutamiento
        • Nantes University Hospital
    • Île-de-France Region
      • Créteil, Île-de-France Region, Francia, 94000
        • Reclutamiento
        • Hospital Henri Mondor
      • Paris, Île-de-France Region, Francia, 75015
        • Reclutamiento
        • Hopital Necker
      • Paris, Île-de-France Region, Francia, 75010
        • Reclutamiento
        • Saint Louis Hospital
      • Athens, Grecia, 11528
        • Reclutamiento
        • General Hospital of Athens Alexandra
    • Attica
      • Athens, Attica, Grecia, 10676
        • Reclutamiento
        • Evangelismos General Hospital
      • Haifa, Israel, 3109601
        • Reclutamiento
        • Rambam Health Care Campus
      • Jerusalem, Israel, 91120
        • Reclutamiento
        • Hadassah Medical Center
    • Central District
      • Ramat Gan, Central District, Israel, 5265601
        • Reclutamiento
        • Sheba Medical Center

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

General Key Inclusion Criteria:

  1. Eastern Cooperative Oncology Group (ECOG) performance status ≤1
  2. Participants must have measurable disease as defined in the protocol according to IMWG consensus criteria
  3. Adequate creatinine clearance, hematologic function and hepatic function, as defined in protocol
  4. Life expectancy of at least 6 months

Cohort Specific Inclusion Criteria:

For cohorts 1-6, each participant must have RRMM with progression following at least 3 lines of therapy, or at least 2 lines of therapy and either prior exposure to at least 1 anti-CD38 antibody, 1 immunomodulatory imide drug (IMiD) and 1 Proteasome Inhibitor (PI), or double-refractory to 1 PI and 1 IMiD, or the combination of 1 PI and 1 IMiD Cohort 1: Prior treatment with daratumumab is allowed if previously tolerated, as described in the protocol Cohort 2: Prior treatment with carfilzomib is allowed if previously tolerated at the approved full dose, as described in the protocol Cohort 3: Prior treatment with lenalidomide is allowed if previously tolerated at the approved full dose, as described in the protocol Cohort 4: Prior treatment with bortezomib is allowed if previously tolerated at the approved full dose, as described in the protocol Cohort 5: Prior treatment with pomalidomide is allowed if previously tolerated at the approved full dose, as described in the protocol Cohort 6: Prior treatment with isatuximab is allowed if previously tolerated, as described in the protocol

Cohort 7 and 8:

  1. For participants without measurable disease by biochemical parameters [serum or urine M-protein, or serum involved Free Light Chain (FLC)], presence of at least 1 soft tissue plasmacytoma with a single diameter of ≥2 cm
  2. RRMM with progressive disease and received at least 3 lines of therapy including exposure to at least 1 anti-CD38 antibody, 1 IMiD, and 1 PI or triple-class refractory disease (anti-CD38 antibody, IMiD, PI) Cohort 9: Progressive RRMM in participants with triple-class refractory disease (anti-CD38 antibody, IMiD, PI) after at least 3 lines of therapy Cohort 10: Progressive RRMM after at least 3 lines of therapy including exposure to at least 1 anti-CD38 antibody, 1 IMiD, and 1 PI

General Key Exclusion Criteria:

  1. Diagnosis of plasma cell leukemia, primary light-chain amyloidosis (excluding myeloma associated amyloidosis), Waldenström macroglobulinemia (lymphoplasmacytic lymphoma), or POEMS syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, and Skin changes)
  2. Participants with known MM brain lesions or meningeal involvement
  3. Treatment with any systemic anti-myeloma therapy within 5 half-lives or within 21 days prior to first administration of study drug regimen, whichever is shorter
  4. History of allogeneic and autologous stem cell transplantation, as described in the protocol
  5. Unless stated otherwise in a specific sub-protocol, prior treatment with a T cell-based immunotherapy directed against B-Cell Maturation Antigen (BCMA) bispecific antibodies and Bispecific T-cell Engagers (BiTEs), and BCMA Chimeric Antigen Receptor (CAR) T cells (Note: BCMA antibody-drug conjugates are not excluded)
  6. History of progressive multifocal leukoencephalopathy, neurodegenerative condition or Central Nervous System (CNS) movement disorder or participants with a history of seizure within 12 months prior to study enrollment are excluded
  7. Live or attenuated vaccination within 28 days prior to first study drug regimen administration with a vector that has replicative potential
  8. Cardiac ejection fraction <40% by Echocardiogram (Echo) or Multigated Acquisition (MUGA) scan

Cohort Specific Exclusion Criteria:

Cohort 2: Dose expansion: Prior treatment with a BCMA-directed CAR T-cell therapy will not be exclusionary if completed at least 12 weeks prior to first study treatment Cohort 3: Known malabsorption syndrome or pre-existing gastrointestinal (GI) condition that may impair absorption of lenalidomide; delivery of lenalidomide via nasogastric tube or gastrostomy tube is not allowed Cohort 4: Peripheral neuropathy grade ≥2 Cohort 5: Known malabsorption syndrome or pre-existing GI conditions that may impair absorption of pomalidomide; delivery of pomalidomide via nasogastric tube or gastrostomy tube is not allowed

Cohort 7:

  1. Prior treatment with anti-Lymphocyte Activation Gene 3 (LAG-3) agents. Prior exposure to vaccine therapies or other immune checkpoint modulating therapies such as anti-Programmed cell Death Protein 1 (PD-1) antibodies is permitted, as described in the protocol
  2. Ongoing or recent (within 2 years) evidence of an autoimmune disease that has required systemic treatment with immunosuppressive agents, as described in the protocol
  3. Prior solid organ transplant
  4. History of grade ≥3 immune-mediated adverse events (with the exclusion of endocrinopathies that are fully controlled by hormone replacement) from prior checkpoint inhibitor therapies

Cohort 8:

  1. Prior treatment with anti-PD-1 or anti-PD-L1 agents. Prior exposure to vaccine therapies or other immune checkpoint modulating therapies such as anti-Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) antibodies is permitted, as described in the protocol
  2. Encephalitis or meningitis in the year prior to enrollment
  3. History of interstitial lung disease (eg, idiopathic pulmonary fibrosis or organizing pneumonia), of active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management, or of pneumonitis within the last 5 years. A history of radiation pneumonitis in the radiation field is permitted as long as pneumonitis resolved ≥6 months prior to enrollment
  4. Ongoing or recent (within 2 years) evidence of an autoimmune disease that has required systemic treatment with immunosuppressive agents, as described in the protocol.
  5. Prior solid organ transplant
  6. History of grade ≥3 immune-mediated adverse events (with the exclusion of endocrinopathies that are fully controlled by hormone replacement) from prior checkpoint inhibitor therapies

Cohort 9:

  1. Abnormal QT interval corrected by Fridericia's formula (QTcF), as described in the protocol
  2. Use of concomitant medications that are known to prolong the QT/QTcF interval including Class Ia and Class III antiarrhythmics at the time of informed consent
  3. Ongoing use or anticipated use of food or drugs that are known strong/moderate cytochrome P450 (CYP)3A4 inhibitors, or strong CYP3A inducers within 14 days prior to first dose of nirogacestat
  4. Known malabsorption syndrome or existing gastrointestinal GI condition that may impair absorption of nirogacestat; delivery of nirogacestat via nasogastric tube or gastrostomy tube is not allowed

Cohort 10:

  1. Known or suspected active Epstein-Barr Virus (EBV) infection
  2. Known history of Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS)
  3. Prior treatment with cevostamab or another agent with the same target [Fragment crystallizable Receptor-like 5 (FcRH5)]

Dose finding portion: Prior treatment with any BCMA-directed immunotherapy will not be exclusionary, as described in the protocol Dose expansion portion: Prior treatment with any T cell-engaging bispecific antibody directed against BCMA will be exclusionary, as described in the protocol

NOTE: Other protocol defined inclusion/exclusion criteria apply

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: No aleatorizado
  • Modelo Intervencionista: Asignación Secuencial
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Cohort 1: Linvoseltamab + Daratumumab

Linvoseltamab + Daratumumab

Administered per the protocol

Otros nombres:
  • REGN5458
  • Lynocisyfic ™

Administered per the protocol

Otros nombres:
  • Darzalex®; Darzalex Faspro™
Experimental: Cohort 2: Linvoseltamab + Carfilzomib

Linvoseltamab + Carfilzomib

Administered per the protocol

Otros nombres:
  • REGN5458
  • Lynocisyfic ™

Administered per the protocol

Otros nombres:
  • Kyprolis®
Experimental: Cohort 3: Linvoseltamab + Lenalidomide

Linvoseltamab + Lenalidomide

Administered per the protocol

Otros nombres:
  • REGN5458
  • Lynocisyfic ™

Administered per the protocol

Otros nombres:
  • Revlimid®
Experimental: Cohort 4: Linvoseltamab + Bortezomib

Linvoseltamab + Bortezomib

Administered per the protocol

Otros nombres:
  • REGN5458
  • Lynocisyfic ™

Administered per the protocol

Otros nombres:
  • Velcade®
Experimental: Cohort 5: Linvoseltamab + Pomalidomide

Linvoseltamab + Pomalidomide

Administered per the protocol

Otros nombres:
  • REGN5458
  • Lynocisyfic ™

Administered per the protocol

Otros nombres:
  • Imnovid, Pomalyst®
Experimental: Cohort 6: Linvoseltamab + Isatuximab

Linvoseltamab + Isatuximab

Administered per the protocol

Otros nombres:
  • REGN5458
  • Lynocisyfic ™

Administered per the protocol

Otros nombres:
  • Sarclisa®
Experimental: Cohort 7: Linvoseltamab + Fianlimab

Linvoseltamab + Fianlimab

Administered per the protocol

Otros nombres:
  • REGN5458
  • Lynocisyfic ™

Administered per the protocol

Otros nombres:
  • REGN3767
Experimental: Cohort 8: Linvoseltamab + Cemiplimab

Linvoseltamab + Cemiplimab

Administered per the protocol

Otros nombres:
  • REGN5458
  • Lynocisyfic ™

Administered per the protocol

Otros nombres:
  • REGN2810
  • LIBTAYO
Experimental: Cohort 9: Linvoseltamab + Nirogacestat

Linvoseltamab + Nirogacestat

Administered per the protocol

Otros nombres:
  • REGN5458
  • Lynocisyfic ™

Administered per the protocol

Otros nombres:
  • PF-03084014
Experimental: Cohort 10: Linvoseltamab + Cevostamab

Linvoseltamab + Cevostamab

Administered per the protocol

Otros nombres:
  • REGN5458
  • Lynocisyfic ™

Administered per the protocol

Otros nombres:
  • RO7187797
  • BFCR4350A

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Incidencia de eventos adversos graves (SAE)
Periodo de tiempo: Hasta 5 Años
Hasta 5 Años
Gravedad de los TEAE
Periodo de tiempo: Hasta 5 Años
Hasta 5 Años
Gravedad de los SAE
Periodo de tiempo: Hasta 5 Años
Hasta 5 Años
Gravedad de los AESI
Periodo de tiempo: Hasta 5 Años
Hasta 5 Años
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Periodo de tiempo: Up to 5 Years
Up to 5 Years
Incidence of Adverse Events of Special Interest (AESIs)
Periodo de tiempo: Up to 5 Years
Up to 5 Years
Incidence of Dose Limiting Toxicities (DLTs) for each study regimen during the observation period
Periodo de tiempo: Up to 28 Days

Dose finding portion only

Up to 28 Days
Incidence of laboratory abnormalities
Periodo de tiempo: Up to 5 Years

≥ grade 3 per National Cancer Institute-Common Terminology Criteria for Adverse Events [NCI-CTCAE v5.0]

Up to 5 Years

Medidas de resultado secundarias

Medida de resultado
Periodo de tiempo
Supervivencia general (SG)
Periodo de tiempo: Hasta 5 Años
Hasta 5 Años
Concentraciones de linvoseltamab total en suero a lo largo del tiempo
Periodo de tiempo: Hasta 5 años
Hasta 5 años
Overall Response Rate (ORR) as measured by International Myeloma Working Group (IMWG) criteria
Periodo de tiempo: Up to 5 Years
Up to 5 Years
Duration of Response (DOR) by IMWG criteria
Periodo de tiempo: Up to 5 Years
Up to 5 Years
Progression-Free Survival (PFS) as measured by IMWG criteria
Periodo de tiempo: Up to 5 Years
Up to 5 Years
Rate of Minimal Residual Disease (MRD) negative status by IMWG criteria
Periodo de tiempo: Up to 5 Years
Up to 5 Years
Incidence over time of Anti-Drug Antibodies (ADAs) to linvoseltamab
Periodo de tiempo: Up to 5 Years
Up to 5 Years

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Director de estudio: Clinical Trial Management, Regeneron Pharmaceuticals

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

17 de agosto de 2022

Finalización primaria (Estimado)

25 de marzo de 2028

Finalización del estudio (Estimado)

24 de marzo de 2032

Fechas de registro del estudio

Enviado por primera vez

18 de noviembre de 2021

Primero enviado que cumplió con los criterios de control de calidad

18 de noviembre de 2021

Publicado por primera vez (Actual)

30 de noviembre de 2021

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

5 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

2 de noviembre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Marco de tiempo para compartir IPD

When Regeneron has:

  • received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
  • made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
  • the legal authority to share the data, and
  • ensured the ability to protect participant privacy

Criterios de acceso compartido de IPD

Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA
  • CIF
  • CÓDIGO_ANALÍTICO
  • RSC

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir